Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

Halozyme Therapeutics, Inc. announced today that the European Commission has granted Roche European Union marketing authorization for the use of a time-saving subcutaneous formulation of Herceptin (trastuzumab) for the treatment of HER2-positive breast cancer.

2 Sep 2013

Certain Hodgkin lymphoma treatments put patients at increased risk for stomach cancer

Hodgkin lymphoma survivors who received certain radiation and chemotherapy regimens were at increased risk of subsequently developing stomach cancer, according to a study by scientists at the National Cancer Institute, part of the National Institutes of Health.

28 Aug 2013

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Ceptaris Therapeutics, Inc., a privately held, specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration has granted marketing approval for the orphan drug VALCHLOR (mechlorethamine) gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

26 Aug 2013

Report demonstrates clinical use of novel biomarker to assess cancer progression, inflammation

A groundbreaking peer reviewed case report by Dr. Isaac Eliaz, M.D. of Amitabha Medical Clinic, demonstrates for the first time the clinical use of novel biomarker galectin-3 to assess cancer progression and inflammation.

19 Aug 2013

Study: Immune-regulating molecules can trigger lymphomas

A small group of immune-regulating molecules, when overproduced even moderately, can trigger the blood cancers known as lymphomas, according to a new study led by scientists from The Scripps Research Institute (TSRI).

9 Aug 2013

Eisai's investigational compound receives orphan drug designation for cutaneous t-cell lymphoma

Eisai Inc. announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell lymphoma. E7777 is designed to have an improved purity profile and manufacturing process.

9 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

A more precise method for determining bone marrow involvement in patients with diffuse large B-cell lymphoma-a key factor in tailoring patient management plans-has been identified by researchers in a study published in the August issue of The Journal of Nuclear Medicine.

2 Aug 2013

Study offers new hope for treatment of diffuse large B-cell lymphoma

Researchers have discovered how an experimental drug is capable of completely eradicating human lymphoma in mice after just five doses. The study, led by researchers at Weill Cornell Medical College, sets the stage for testing the drug in clinical trials of diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, itself the seventh most frequently diagnosed cancer in the U.S.

2 Aug 2013

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe forms of vasculitis, or inflammation of the blood vessels, a study has found.

1 Aug 2013

Incidence of blood cancer is significantly higher in regions near facilities that release benzene

The incidence of a particular type of blood cancer is significantly higher in regions near facilities that release the chemical benzene into the environment. That is the conclusion of a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. This and other studies like it will be critical to identifying and enacting public health policies to decrease or prevent cancer.

29 Jul 2013

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

Genentech announces that Phase III CLL11 study meets primary endpoint

Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.

24 Jul 2013

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully-integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that, through a wholly-owned subsidiary, the company entered into an agreement to acquire Talon Therapeutics, Inc., a biopharmaceutical company based in South San Francisco, California, and expects to complete the acquisition within one day.

17 Jul 2013

Cancer patients who receive chest radiation should screen for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years, according to the European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology (ESC) and the American Society of Echocardiography (ASE).

17 Jul 2013

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

16 Jul 2013

Childhood cancer survivors can still get pregnant despite increased risk of infertility

Although women who survived childhood cancer face an increased risk of infertility, nearly two-thirds of those who tried unsuccessfully to become pregnant for at least a year eventually conceived, according to clinical researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Brigham and Women's Hospital. This is comparable to the rate of eventual pregnancy among all clinically infertile women.

15 Jul 2013

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical.

11 Jul 2013

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the Company has been granted market access by the Italian Medicines Agency for the medicinal product PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed 2 or 3 prior lines of therapy).

8 Jul 2013

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 trial.

3 Jul 2013

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Roche's Herceptin formulation wins EU approval for treatment of HER2-positive breast cancer

Certain Hodgkin lymphoma treatments put patients at increased risk for stomach cancer

FDA grants marketing approval for VALCHLOR gel for treatment of early stage CTCL

Report demonstrates clinical use of novel biomarker to assess cancer progression, inflammation

Study: Immune-regulating molecules can trigger lymphomas

Eisai's investigational compound receives orphan drug designation for cutaneous t-cell lymphoma

ImmunoGen reports net loss of $21.9 million in Q4 2013

Researchers identify precise method for determining bone marrow involvement in DLBCL patients

Study offers new hope for treatment of diffuse large B-cell lymphoma

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Incidence of blood cancer is significantly higher in regions near facilities that release benzene

Technique for developing more targeted drugs using molecular "robots"

Genentech announces that Phase III CLL11 study meets primary endpoint

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Cancer patients who receive chest radiation should screen for heart disease every 5-10 years

Cancer patients who receive chest radiation should be screened for heart disease every 5-10 years

Childhood cancer survivors can still get pregnant despite increased risk of infertility

New study evaluates effectiveness of radioimmunotherapy in lymphoma patients

AIFA grants market access for CTI's PIXUVRI to treat patients with aggressive B-cell NHL

Genentech's obinutuzumab gets FDA Priority Review for chronic lymphocytic leukemia

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in